Patents by Inventor Jonathan McDunn

Jonathan McDunn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Membrane-permeant peptide complexes for treatment of sepsis
    Patent number: 8038984
    Abstract: Methods and compositions for treating sepsis using cell membrane-permeant peptide conjugate covalent compounds having target cell specificity are provided.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: October 18, 2011
    Assignee: Washington University
    Inventors: Richard Hotchkiss, David Piwnica-Worms, Jonathan McDunn
  • MEMBRANE-PERMEANT PEPTIDE COMPLEXES FOR TREATMENT OF SEPSIS
    Publication number: 20100121031
    Abstract: Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided.
    Type: Application
    Filed: November 12, 2009
    Publication date: May 13, 2010
    Applicant: WASHINGTON UNIVERSITY
    Inventors: Richard Hotchkiss, David Piwnica-Worms, Jonathan McDunn, Ernesto Bernal-Mizrachi
  • Methods and Compositions for Treatment of Sepsis
    Publication number: 20090012025
    Abstract: Methods of treatment of sepsis are disclosed. These methods comprise administering to a subject a composition comprising at least one siRNA directed against at least one gene encoding a pro-apoptotic polypeptide. The pro-apoptotic polypeptide, in some aspects, can be other than Fas or caspase-8. In some embodiments, an siRNA can be directed against a pro-apoptotic component of the mitochondrial pathway, such as a pro-apoptotic bcl-2 protein. In some aspects, an siRNA can be directed against a BH3-only bcl-2 protein, while in other aspects, siRNAs can be directed against multi BH domain Bcl-2 family members such as bax and bak. In some embodiments, an siRNA can be directed against a death receptor pathway molecule such as FADD. In various configurations, a composition can also comprise a cationic lipid such as DOTAP, or nanoparticles comprising a cyclodextrin-containing polycation and a polymer such as a poly(ethylene glycol).
    Type: Application
    Filed: February 11, 2008
    Publication date: January 8, 2009
    Inventors: Richard Hotchkiss, Jonathan McDunn, David Piwnica-Worms, Steven Schwulst
  • Membrane-permeant peptide complexes for treatment of sepsis
    Publication number: 20060263382
    Abstract: Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided.
    Type: Application
    Filed: March 29, 2006
    Publication date: November 23, 2006
    Inventors: Richard Hotchkiss, David Piwnica-Worms, Jonathan McDunn, Ernesto Bernal-Mizrachi
  • Membrane-permeant peptide complexes for treatment of sepsis
    Publication number: 20060166881
    Abstract: Methods and compositions for treating sepsis using cell membrane-permeant peptide conjugate covalent compounds having target cell specificity are provided.
    Type: Application
    Filed: November 23, 2005
    Publication date: July 27, 2006
    Inventors: Richard Hotchkiss, David Piwnica-Worms, Jonathan McDunn